Table 3 Different therapeutic options used in our cohort
Treatment | N (%) |
|---|---|
Conservative | 48 (32) |
Cyclophosphamide | 36 (24) |
Calcineurin inhibitors | 38 (26) |
Antiproliferative agents (MMF/azathioprine) | 21 (14) |
Rituximab/steroid monotherapy/other | 1/3/1 (Total 3%) |